Lilly’s Little Pill: A Sweet Treat for Investors?

by

Now, Eli Lilly (LLY 1.29%)… a rather enormous pharmaceutical factory, isn’t it? For years, these places lumbered along, churning out pills at a sensible, predictable pace. But Lilly? Oh, Lilly is different. It’s sprouted a most peculiar growth, and it all comes down to a rather marvelous, and ever so slightly magical, collection of potions designed to… well, let’s just say help people become a bit less… bulbous.

They’ve concocted a brew called tirzepatide – a terribly long word, isn’t it? – sold as Mounjaro for those with a sugar-balancing problem, and then as Zepbound for those who’ve decided they’ve had quite enough of themselves. It’s a potion that seems to shrink people, and people, it turns out, are rather keen on shrinking. Demand has been positively frantic, even outstripping the factory’s ability to bubble it up quickly enough. Novo Nordisk, a rival potion-maker, has a similar brew, but we won’t dwell on them. They’re rather dull, really.

Lilly’s share price took a bit of a tumble this year, a little hiccup, if you will. But over the past three years? It’s climbed higher than a beanstalk. And now, a rather important date looms – April 10th. Should you sneak a peek at Lilly’s shares before then? Let’s have a proper look, shall we?

Mounjaro and Zepbound

Now, this tirzepatide business is quite clever. First, they offered Mounjaro, and doctors, being resourceful sorts, started prescribing it for those who wished to slim down, even if that wasn’t precisely what it was made for. Then, they officially bottled it as Zepbound, specifically for the shrinking process. It tinkers with the tummy’s signals, a sort of hormonal jiggery-pokery, to curb appetites and tame those pesky sugar levels. It’s a bit like teaching a greedy goblin to eat only one biscuit.

In the latest quarter, Mounjaro and Zepbound together brought in a whopping $11 billion for Lilly. That’s a lot of shrinking, wouldn’t you agree?

Now, these potions aren’t sipped like lemonade. They’re injected, either with a pen or a syringe, a weekly poke, if you will. It’s not the most glamorous process, but people seem willing to endure it.

But here’s the exciting bit. Lilly has submitted another potion, orforglipron, to the American potion-approvers (the FDA, they’re called). It’s a shrinking potion you swallow. And the FDA is expected to announce their decision very soon – on April 10th, in fact. Reuters, those nosey news-gatherers, have let the cat out of the bag.

Novo Nordisk does have a shrinking pill, approved just recently, but Lilly’s version is a bit more… agreeable. The Novo pill demands you take it first thing in the morning, on an empty stomach. Lilly’s? You can take it whenever you please, with or without biscuits. A much more civilized arrangement, wouldn’t you say?

Loading widget...

A Convenient Weight Loss Drug

And convenience, you see, is a powerful thing. It’s much easier to swallow a pill on the go, while gallivanting about, than to lug around syringes and potions. Plus, these pills are cheaper and easier for Lilly to manufacture and store. A higher-margin potion, they call it. A bit greedy, perhaps, but perfectly sensible from a business point of view.

The trial results for orforglipron were rather promising, so there’s good reason to believe the FDA will give it the thumbs-up. Could an approval on April 10th send the share price soaring? And does that mean you should rush out and buy Lilly shares immediately?

An approval would likely give Lilly’s share price a little boost, especially since it’s currently a bit more reasonably priced than it was a few months ago.

So, investors might be eager to jump in at this level, especially with the idea that this new potion could drive even more revenue growth in the coming months. Analysts predict the shrinking potion market could reach almost $100 billion by the end of the decade. A rather enormous sum, wouldn’t you agree? And Lilly, holding 60% of the American market, is perfectly positioned to benefit.

Now, all of this means that buying Lilly shares right now is a rather good idea. But you don’t have to rush. Short-term wobbles in the share price won’t matter much if you hold onto those shares for the long haul.

So, whether you buy Lilly shares today or after April 10th, you could be making a rather fantastic long-term investment move. Just remember, investing is a bit like growing a beanstalk. It takes time, patience, and a little bit of magic.

Read More

2026-03-22 12:14